Castrate Resistant Prostate Cancer Enhertu Therapy

Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.

Trial Details

NCT ID
NCT06610825
Phase
PHASE2
Sponsor
Washington D.C. Veterans Affairs Medical Center
Status
RECRUITING
Cancer Type
Castration-Resistant (CRPC) Prostate Cancer
Interventions
  • Enhertu
Locations (sample)
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637

Key Eligibility Criteria

  • Pathologically confirmed adenocarcinoma of the prostate
  • Diagnosis of mCRPC
  • Documented progression on androgen deprivation and novel hormonal agents, with or without progression on taxane containing regimen
  • Ongoing ADT to maintain serum testosterone levels below 50 ng/dL

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →